Sugi Predict

Sugi Predict / Compounds / SCHEMBL856302

SCHEMBL856302

SCHEMBL856302

CCCCOC(=O)N1CCC(N)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ LMNA P02545 1/20 0.59
▸ POLB P06746 1/20 0.59
▸ GNAI3 P08754 2/20 0.54
▸ GNAO1 P09471 2/20 0.54
▸ GNAI1 P63096 2/20 0.54
▸ GAA P10253 1/20 0.50
▸ NOS3 P29474 1/20 0.44
▸ NOS2 P35228 1/20 0.44
▸ CHRM1 P11229 2/20 0.43
▸ ATM Q13315 2/20 0.43
▸ THRB P10828 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ HRH2 P25021 1/20 0.41
▸ HRH1 P35367 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ P2RY12 Q9H244 1/20 0.41
▸ PKM P14618 1/20 0.40
▸ HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL323088 0.90 SMN1; SMN2 (0.53) SMN1; SMN2LMNAPOLBGNAI3GNAO1
SCHEMBL2778567 0.90 SMN1; SMN2 (0.53) SMN1; SMN2LMNAPOLBGNAI3GNAO1
SCHEMBL14275779 0.90 GAA (0.53) SMN1; SMN2LMNAPOLBGNAI3GNAO1
SCHEMBL7449135 0.86 POLB (0.63) SMN1; SMN2LMNAPOLBGAANOS3
SCHEMBL842129 0.85 SMN1; SMN2 (0.51) SMN1; SMN2LMNAPOLBGNAI3GNAO1
SCHEMBL842128 0.85 SMN1; SMN2 (0.51) SMN1; SMN2LMNAPOLBGNAI3GNAO1
SCHEMBL7339506 0.85 LMNA (0.61) SMN1; SMN2LMNAPOLBGAANOS3
SCHEMBL184778 0.85 LMNA (0.61) SMN1; SMN2LMNAPOLBGAANOS3
SCHEMBL382565 0.84 GAA (0.68) SMN1; SMN2POLBGNAI3GNAO1GNAI1
SCHEMBL5823241 0.84 GAA (0.73) SMN1; SMN2LMNAPOLBGAANOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC (US) 2026-04-16 — — US disclosed
WO-2025099238-A1 COMPOUNDS FOR USE IN THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR (GIST) Universität Duisburg-Essen (DE) 2025-05-15 — — WO disclosed
WO-2024210572-A1 NOVEL IMIDAZOLE DERIVATIVE AND USE THEREOF 주식회사 펠레메드 2024-10-10 — — WO disclosed
US-11932624-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-03-19 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
WO-2023229380-A1 HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF 주식회사 엘지화학 2023-11-30 — — WO disclosed
WO-2023049790-A2 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-30 — — WO disclosed
EP-4121043-A1 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 — — EP disclosed
EP-4076459-A1 PRMT5 INHIBITORS Merck Sharp & Dohme LLC (US) 2022-10-26 — — EP disclosed
WO-2021188948-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
EP-1370568-A1 CHEMICAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2003-12-17 — — EP disclosed
WO-2002074780-A1 CHEMICAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2002-09-26 — — WO disclosed
EP-0960104-A1 N-(AMIDINOPHENYL)-N'-(SUBST.)-3H-2,4-BENZODIAZEPIN-3-ONE DERIVATIVES AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 1999-12-01 — — EP disclosed
EP-0831830-A4 IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORP (US) 1998-12-02 — — EP disclosed
EP-0831830-A1 IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1998-04-01 — — EP disclosed
WO-1997038984-A1 N-(AMIDINOPHENYL)-N'-(SUBST.)-3H-2,4-BENZODIAZEPIN-3-ONE DERIVATIVES AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1997-10-23 — — WO disclosed
WO-1996040143-A1 IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1996-12-19 — — WO disclosed
EP-0708768-A4 TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES SMITHKLINE BEECHAM CORP (US) 1996-08-21 — — EP disclosed
EP-0708768-A1 TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES SMITHKLINE BEECHAM CORPORATION (US) 1996-05-01 — — EP disclosed
WO-1995002591-A1 TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES SMITHKLINE BEECHAM CORPORATION (US) 1995-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 SMN1; SMN2 3149/4885LMNA 2219/4885POLB 845/4885
US-11932624-B2 MDM2 degraders and uses thereof MDM2, TP53, MDM4 SMN1; SMN2 3149/4885LMNA 2219/4885POLB 845/4885
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY BRAF, TTK, MAP4K2 SMN1; SMN2 4434/4885LMNA 3051/4885POLB 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.